Overview

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

This study is a prospective, multicenter, open label cohort study involving MDS/MPN patients. The enrolled patients have symptoms that require treatment, which are classified according to their clinical conditions as follows: those with MDS as the main manifestation are treated with Azacitidine combined with Selinexor; For those with MPN as the main manifestation, treatment with Selinexor combined with Ruxolitinib is used.

Phase:

PHASE2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Azacitidine
selinexor